Which companies overlap with Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company's portfolio?

Top competitors by shared drug class: Sanofi, Boryung Pharmaceutical Co., Ltd, Merck Sharp & Dohme LLC, Novartis, Assistance Publique - Hôpitaux de Paris.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company pipeline: 4 marketed, 0 filed, 4 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 4 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
olmesartan medoxomil + hydrochlorothiazide, if necessary	olmesartan medoxomil + hydrochlorothiazide, if necessary	marketed	Angiotensin II receptor blocker + thiazide diuretic combination	AT1 receptor (angiotensin II type 1 receptor); sodium-chloride cotransporter	Cardiovascular
Perindopril + amlodipine + if necessary, hydrochlorothiazide	Perindopril + amlodipine + if necessary, hydrochlorothiazide	marketed	ACE inhibitor + calcium channel blocker + thiazide diuretic combination	Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter	Cardiovascular
Olmesartan medoxomil tablets low dose	Olmesartan medoxomil tablets low dose	marketed	Angiotensin II receptor blocker (ARB)	AT1 receptor (Angiotensin II type 1 receptor)	Cardiovascular
olmesartan/amlodipine + hydrochlorothiazide, if necessary.	olmesartan/amlodipine + hydrochlorothiazide, if necessary.	marketed	Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic)	Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)	Cardiovascular
VKA-Based Regimen	VKA-Based Regimen	phase 3	Vitamin K antagonist (VKA)	Vitamin K epoxide reductase complex 1 (VKORC1)	Cardiovascular
Olmesartan medoxomil tablets high dose	Olmesartan medoxomil tablets high dose	phase 3	Angiotensin II receptor antagonist	AT1 receptor	Cardiovascular
losartan + hydrochlorothiazide, if necessary	losartan + hydrochlorothiazide, if necessary	phase 3	Angiotensin II receptor antagonist and thiazide diuretic	Angiotensin II receptor	Cardiovascular
nitrendipine + hydrochlorothiazide, if necessary	nitrendipine + hydrochlorothiazide, if necessary	phase 3

Therapeutic area mix

Cardiovascular · 7

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Sanofi · 2 shared drug classes
Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Novartis · 2 shared drug classes
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Baker Heart and Diabetes Institute · 1 shared drug class
Ahn-Gook Pharmaceuticals Co.,Ltd · 1 shared drug class
Arbor Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company:

Cite this brief

Drug Landscape (2026). Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company. Accessed 2026-05-17.